Daron Evans Buys 9,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 9,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $4.60 per share, with a total value of $41,400.00. Following the completion of the transaction, the chief financial officer now owns 140,900 shares of the company’s stock, valued at $648,140. This represents a 6.82 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Rezolute Price Performance

Shares of NASDAQ:RZLT opened at $4.59 on Friday. Rezolute, Inc. has a 1 year low of $0.81 and a 1 year high of $6.19. The company has a market capitalization of $265.96 million, a PE ratio of -3.61 and a beta of 1.01. The business has a fifty day moving average price of $5.16 and a two-hundred day moving average price of $4.77.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.14). Sell-side analysts anticipate that Rezolute, Inc. will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jeppson Wealth Management LLC purchased a new position in Rezolute in the second quarter valued at approximately $45,000. MML Investors Services LLC bought a new stake in shares of Rezolute in the third quarter valued at $57,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Rezolute during the 3rd quarter valued at $65,000. Virtu Financial LLC grew its stake in shares of Rezolute by 58.0% during the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock worth $126,000 after acquiring an additional 9,551 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after acquiring an additional 22,660 shares during the period. 82.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RZLT. BTIG Research boosted their price objective on Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Rezolute in a report on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a research report on Monday, November 4th. JMP Securities reaffirmed a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Finally, Guggenheim assumed coverage on shares of Rezolute in a report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $24.13.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.